NEW YORK, Sept. 22 (GenomeWeb News) - Myriad Proteomics said today that it has changed its name to Prolexys Pharmaceuticals to more accurately represent its strategic focus "after making the conversion from a technology-focused organization to a drug discovery company."
Prolexys plans to use information about protein interactions to discover and validate new drug targets.
"Our new name, Prolexys, culminates the organizational and strategic transformation that has occurred here," said Thomas Ingolia, president and CEO. "As we continue to obtain disease biology information through the use of high-throughput proteomics technologies, we are taking a number of pathway discoveries through the process of validation, screening, and lead compound identification."
Ingolia said the company is focusing on neurodegenerative diseases and oncology.